Vir Biotechnology, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−3.79%
vs ±11.6% implied · ×0.33
shaded = implied · ▲▼ = realized
Vir Biotechnology has 3 disclosed suppliers and 5 disclosed customers in SEC filings.
SentenceConcurrently with the execution of the Astellas Agreement, we also entered into the Astellas SPA, pursuant to which Astellas has agreed to purchase 7,239,382 shares of our common stock for an aggregate purchase price of approximately $75 million, subject to customary closing conditions and the closing of the Astellas Agreement.
VIR 10-Kaccession 0001628280-26-010749
SentenceThe decrease in grant revenue for the year ended December 31, 2025 compared to the same period in 2024 was primarily due to lower revenue recognized in accordance with our agreement with BARDA and to a lesser extent, lower revenue recognized from the Gates Foundation.
VIR 10-Kaccession 0001628280-26-010749
SentenceThe decrease in grant revenue for the year ended December 31, 2025 compared to the same period in 2024 was primarily due to lower revenue recognized in accordance with our agreement with BARDA and to a lesser extent, lower revenue recognized from the Gates Foundation.
VIR 10-Kaccession 0001628280-26-010749
SentenceAlthough we have previously recognized revenue from our profit-share related to sotrovimab under our definitive collaboration agreement with GSK executed in June 2020, or the 2020 GSK Agreement, we expect to continue to incur net operating losses for the foreseeable future.
VIR 10-Kaccession 0001628280-26-010749
SentenceTo support global commercialization of the combination of tobevibart and elebsiran for the treatment of CHD, the Company granted Norgine an exclusive commercial license in Europe, Australia and New Zealand.
VIR 10-Kaccession 0001628280-26-010749
Vir Biotechnology, Inc.
11.46
Linked news
Expected move
Inputsspot 11.30exp Nov 20ATM strike 11ATM straddle 1.52IV 71%